Interest in complement inhibition gains momentum

Article

Interest in complement factor inhibition in the treatment of age-related macular degeneration (AMD) continues to gain momentum with two developers making separate announcements on progress with their AMD therapy hopefuls.

Interest in complement factor inhibition in the treatment of age-related macular degeneration (AMD) continues to gain momentum with two developers making separate announcements on progress with their AMD therapy hopefuls.

Potentia Pharmaceuticals' candidate, POT-4, is the first complement inhibitor to be tested in humans. It is designed to reduce inflammation and modify the upregulation of factors influencing angiogenesis by binding to complement component C3. Early safety results from the Phase I trial have so far been positive. POT-4 potentially has application against both wet and dry AMD. The latest data from the Phase I ASaP of POT-4 are due to be announced during the Retina Subspecialty Day, on November 7, at this year's meeting of the American Academy of Ophthalmology.

In a separate announcement, Ophthotech Corp. has now begun enrolment in the Phase I trial of its drug candidate ARC1905, an anti-C5 complement aptamer that also incorporates anti-VEGF properties. ARC1905 is undergoing safety and tolerability testing, and is also intended for the treatment of both wet and dry AMD.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.